- ESR1: Design, Synthesis and Biochemical evaluation of novel serine protease inhibitors. University of Antwerp
- ESR2: Design, Synthesis and Biochemical evaluation of novel RIPK1 inhibitors. University of Antwerp
- ESR3: Implementation of in vivo models to identify potential candidates for DED treatment. University of Antwerp
- ESR4: Valorisation of natural compounds and their evaluation as therapeutic agents for ocular surface inflammatory diseases.University of Valladolid
- ESR5: Upscaling of lead compounds from WP1 and enantioselective synthesis of the serine protease inhibitor UAMC-00050. Latvian Institute of Organic Synthesis
- ESR6: Development of new carriers to improve the bioavailability of topic formulations to treat ocular surface inflammatory diseases. University of Valladolid
- ESR7: Drug penetration to ocular surface tissues. University of Eastern Finland
- ESR8: Development of new biomarkers for Dry Eye Disease. Sorbonne Université
- ESR9: The nociceptive pathway in dry eye disease and ocular surface pain models. Sorbonne Université
- ESR10: Dry eye therapy using cannabinoid ligands in a water-free delivery platform. University Hospital of Cologne
- ESR11: Development of novel diagnostic tools for dry-eye disease using optical coherence tomography (OCT) and confocal microscopy. University Hospital of Cologne
- ESR12: Extraction of hyaluronic acid and chondroitin sulphate from marine biomass and their evaluation as bioactive polymers in ocular carrier formulation. The Institute of Experimental Biology and Technology